Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

The precise quantification of residual host cell proteins (HCPs) in adeno-associated virus (AAV) vector preparations is a core component of a robust Chemistry, Manufacturing, and Controls (CMC) strategy. Process-related impurities derived from production systems like Spodoptera frugiperda (Sf9) or Human Embryonic Kidney (HEK293) cells represent a potential risk to a product’s biological activity and safety profile. A rigorous analytical program to detect and quantify these residuals is necessary for minimizing clinical risk and satisfying global regulatory expectations, including those of the MHRA for Investigational Medicinal Product Dossier (IMPD) submissions.

Characterization Challenges in Common AAV Production Platforms

The choice of AAV production system has direct consequences for the subsequent analytical strategy. Both Sf9 and HEK293 platforms can yield high-titer vectors, but their impurity profiles are distinct and require tailored characterization.

HEK293 System:

• Transient transfection of HEK293 cells is a widely used method for producing various AAV serotypes (e.g., AAV2, AAV8, AAV9).

• The primary analytical challenge involves creating assays that can distinguish between the therapeutic protein product and a complex background of human-derived HCPs.

• Co-purifying proteins, such as chaperones or DNA-binding proteins, can be particularly difficult to remove and require sensitive, specific assays for their detection.

Sf9/Baculovirus System:

• This platform offers high yields and scalability but introduces proteins from both the insect cell line and the baculovirus expression vector.

• A key consideration is the potential for patient immunogenicity to baculovirus or insect cell proteins, which are foreign to the human system.

• Establishing a comprehensive process-specific HCP assay is necessary to ensure these unique impurities are cleared effectively during downstream processing.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. We rely on Franklin Biolabs for our AAV-vector based gene therapy candidate development and hope to continue the collaboration for years to come.”
— Biotech Partner

An Analytics-Led Approach to De-Risking AAV Programs

A well-characterized product substance is the basis for a successful IND submission, which our teams consistently achieve within an 18-24 month timeline. Our analytical philosophy is informed by decades of research into vector biology and its translational implications. Understanding that AAV vectors can inherently avoid certain T-cell responses (PMID: 20234342) places a greater focus on controlling extrinsic factors like process-related impurities. The introduction of immunogenic HCPs could negate the vector’s naturally low immunogenic profile and alter the therapeutic profile.

Observed differences in vector transduction patterns across species (PMID: 21778099) also highlight the limitations of relying solely on in vivo models to predict human outcomes. This variability reinforces the need for an exceptionally well-defined product. By minimizing manufacturing variability and thoroughly characterizing impurities like HCPs, we help ensure that preclinical data reflect the vector’s biological activity, not an artifact of the production process.

The Franklin Biolabs brand launched in 2024, building upon a scientific legacy that has achieved a 100% successful IND rate for its programs since 2019.